Hormone Planning Period
A guide to the planning period for new patients interested in gender-affirming hormone therapy.
The following is a guide to the planning period for trans and non-binary (TNB) patients who have reached Tanner Stage V in pubertal development and are interested in hormone therapy (for options for pubertal youth, please refer to the Endocrine Society Guidelines and this CMAJ article). It is more important that the tasks of the planning period are completed, rather than a certain number of visits logged or period of time elapsed.
The planning period is important for:
- Establishing rapport with the patient
- Ensuring the patient has all the information they need to start hormone therapy
- Ensuring the patient feels prepared
- Offering additional supports to the patient as needed
Patient History
TNB patients invariably experience some degree of minority stress, and many are exposed to gender-based interpersonal violence. Negative experiences in healthcare settings can further exacerbate the effects of this trauma. In addition to ensuring a gender-affirming approach to all patients, it is encouraged that providers be familiar with and practice trauma-informed care.
Facilitate a trusting, open relationship by using respectful language.
- Always refer to your patient by their chosen name and pronouns. If you are unsure, ask the patient how they would like to be addressed.
- Check in with your patient regularly about changes to their name or pronouns, and encourage them to let you know if those change in the future.
- When referring to a patient, use language that describes their present identity, not their sex assigned at birth.
General Medical Intake
This includes obtaining past records from previous provider(s), if this is a new patient.
Gender History
Speaking with clients about their history and experience with gender is not something healthcare providers are typically taught in training. However, it is an important part of getting to know a gender-diverse patient and informs the discussion around developing an individualized care plan. Reassure your patient that there are no “wrong answers” and no specific narrative the provider is looking to hear. Not all TNB people experience gender dysphoria or display gender diversity in childhood; TNB identities may emerge at any point in life.
Baseline Data
Focused Physical Exam
A focused physical exam is generally recommended prior to the initiation of hormone therapy. The exam should include screening for problems such as hypertension, obesity, and active liver disease which may increase the risks of hormone therapy.
A baseline breast exam (i.e., to assess for the presence of baseline gynecomastia) may be helpful for transfeminine patients, particularly those who may wish to pursue publicly-funded breast augmentation.*
*MOH funding for breast augmentation is restricted to those who experience no breast development after 12 months on estrogen.
Vitals
Baseline measures include blood pressure, height and weight.
Bloodwork
Laboratory tests are used to investigate for existing health problems such as liver dysfunction, high cholesterol, or diabetes. If present, these conditions should ideally be managed prior to or concurrently with starting hormone therapy. The values will also provide a useful baseline to help with the future monitoring for endocrine changes. The measurement of hormone levels may reveal whether any exogenous hormones are being taken; any major irregularities could also indicate an intersex condition.
Patient Education
Risk Management
Have precautions been optimally managed or is a management plan in place?
Each hormone will have its own specific considerations and precautions which are explained in more detail in the feminizing and masculinizing hormone therapy sections. However, it is worthwhile to address general considerations and precautions with hormone use.
Denying access to hormones can do much more harm than the possible risks of treatment. With an informed-consent approach (support, education and consent) many providers will initiate hormones with individuals with higher risk profiles when it increases their quality of life/chance of survival greatly.
Lifestyle Considerations
Starting hormone therapy and the prospect of aligning one’s body with an internal sense of gender can create an opportunity for patients to develop a new relationship with their body and initiate positive lifestyle changes. We have often seen this time of transition inspire lasting health improvements.
Smoking and obesity increase the risks associated with hormone therapy. It is worthwhile for the provider and patient to work together to reduce these risks where possible, with the understanding that this is not always feasible before starting treatment and that a harm reduction approach may be necessary. Substance use disorders, whether involving alcohol, street drugs or prescription medications, may introduce additional risks that should be considered.
Mental Health Considerations
TNB patients invariably experience some degree of minority stress. They have a higher prevalence of stress-related mental health conditions, such as depression, anxiety and substance use disorders. The presence of mental health concerns does not preclude access to hormone therapy; rather, according to WPATH, these concerns should ideally be “reasonably well controlled prior to or concurrently with hormone therapy.” There is no convincing evidence that hormone therapy causes or worsens mental health conditions; in fact, many studies have shown consistent improvements in psychological functioning. Nonetheless, caution may be prudent in patients with bipolar disorder or psychotic disorders, particularly when these are sub-optimally managed. Primary care providers can help patients optimize their mental health in preparation for and throughout medical transition.
For patients with complex, severe or poorly controlled mental health conditions, a referral to a specialized centre or to a psychiatrist with experience working with TNB patients can be helpful.
Although acute suicidality has previously been considered a contraindication to hormone therapy, particularly testosterone, there may be cases where a patient at significant risk of suicide but able to provide informed consent may benefit greatly from starting hormones. This may be especially true when intense gender dysphoria is the main source of psychological distress.
We suggest these situations be approached on a case-by-case basis, weighing the risks and benefits of hormone therapy in relation to the patient’s mental health. In some cases, the best course may be to start low-dose therapy while implementing suicide risk reduction strategies, such as establishing a crisis plan and connecting the patient with additional mental health support. If a patient is experiencing a major depressive episode, pharmacotherapy should be discussed.
Differential Diagnosis
Rule out other possible diagnoses (e.g., schizophrenia and other psychotic disorders, dissociative disorder and body dysmorphic disorder). Such diagnoses are rarely found to be underlying the desire for gender-affirming treatment, but can occur and thus should be ruled out. If the presentation is unclear, it is appropriate to obtain the opinion of a psychiatrist who is experienced in working with TNB people if possible.
Ensure there is no evidence of an intersex condition.
Genital examination was previously recommended before starting hormone therapy; however, we suggest that inquiry into any history suggestive of an intersex condition, such as ambiguous genitalia or unexpected pubertal changes for sex assigned at birth, along with baseline hormone levels within expected ranges, is sufficient. Findings suggestive of an intersex condition merit further investigation or consultation with an endocrinologist before treatment.
Does the patient meet the criteria for gender dysphoria/gender incongruence?
The provision of hormone therapy has generally been preceded by a diagnosis of Gender Dysphoria as outlined in the Diagnostic and Statistics Manual, Volume 5 (DSM-5). There has been a great deal of debate in both the medical and TNB communities around the appropriateness of using a psychiatric diagnosis (or a diagnosis at all) for TNB individuals. The aim to destigmatize gender diversity while securing access to appropriate treatment has been a central dilemma in this debate.
The revision of the diagnosis (previously called Gender Identity Disorder) and associated diagnostic criteria in 2013’s DSM-5 represented a step towards depathologizing gender difference and validating the spectrum of gender identities.
View criteria for DSM-5 Diagnosis of Gender Dysphoria.
In 2019, the WHO took a step further towards the depathologization of TNB identities in their International Statistical Classification of Diseases and Related Health Problems (ICD-11). They have renamed the diagnosis Gender Incongruence and removed the diagnosis from the category of mental health disorders, placing it instead in a category of “Conditions Related to Sexual Health.” This terminology has been adopted by WPATH in their most recent Stands of Care (Version 8).
Harm Reduction
Fast-Tracking Through the Planning Period
Provision of hormone treatment may be undertaken, in some cases, without completing all of the usual tasks of the planning period. Situations that may warrant a degree of ‘fast-tracking’ through the planning period include:
- A patient who is already using hormones without a prescription
- A patient who has marked distress regarding their gender presentation
- The patient’s medical and/or gender history are well known prior to the patient seeking hormone therapy
- If another knowledgeable provider has recently performed part or all of the assessment and the associated records are available for review or a conversation with the prior provider can be arranged, all tasks of the assessment period need not be repeated